Unknown PHASE2 INTERVENTIONAL 1-arm NCT04065308

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma (Dara_DCEP)

A Phase II Trial to Evaluate the Efficacy of Daratumumab With DCEP in Multiply Myeloma Patients With Plasmacytoma Who Fail to Achieve Complete Remission With Bortezomib Containing Induction Regimen

Sponsor: Seoul National University Hospital

Conditions Daratumumab Multiple Myeloma in Relapse Plasmacytoma

Interventions Drug Combinations

Updated 6 times since 2019 Last updated: Aug 21, 2019 Started: Jan 14, 2019 Primary completion: Dec 21, 2019 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04065308, this PHASE2 trial focuses on Daratumumab and Multiple Myeloma in Relapse and remains ongoing. Sponsored by Seoul National University Hospital, it has been updated 6 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Nov 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2021 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Sep 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea